May 01, 2026

Upgraded lens design features CooperVision Binocular Progressive System® – an innovative 3 Add multifocal system – optimising vision for all levels of presbyopia.1

Fareham, 1st May 2026 – CooperVision today announced the launch in the UK and Ireland of new clariti® 1 day multifocal contact lenses with CooperVision Binocular Progressive System® – an innovative 3 Add multifocal system. The upgraded lenses feature several next-generation enhancements designed to provide optimised vision1 and high levels of comfort2,3 for presbyopic patients, along with an easy and successful fitting experience4 for eye care professionals (ECPs).

The new clariti® 1 day multifocal builds on the brand’s established reputation as a popular choice among ECPs for presbyopes who need crisp vision1 and good comfort6,7 alongside great value.6,8 Now, incorporating CooperVision’s latest innovations, the upgraded lens elevates the performance of the clariti® 1 day multifocal lens*6,7 and is available throughout the UK & Ireland.

“The launch of the new clariti® 1 day multifocal with Binocular Progressive System™ represents a significant step forward for our clariti® 1 day portfolio,” said Lucy Davies, Director of Marketing & Professional Affairs at CooperVision UK & Ireland. “This upgrade reflects our continuous commitment to innovation across our silicone hydrogel one-day product families. By applying the same advanced lens design introduced in our highly regarded MyDay® multifocal,6,7 we’re giving ECPs across the UK & Ireland an even stronger tool to address the growing needs of presbyopic patients – and reinforcing clariti® 1 day’s position as a complete and compelling portfolio.”

The new clariti® 1 day multifocal maintains the features ECPs and wearers value about the lens,†‡§à 6,8 while incorporating CooperVision Binocular Progressive System® for improved visual acuity at all distances.*6,7 Key features include:

  • CooperVision Binocular Progressive System® – uses different lens designs to optimise vision for all levels of presbyopia.1

  • Optimised Comfort Edge™ – design helps to provide good comfort.6,7

  • WetLoc® Technology – helping to maintain lens hydration throughout the day.6

Simplified Fitting, Strong Fit Success

The CooperVision Binocular Progressive System® provides a highly effective fitting approach designed to make it easier for ECPs to achieve the right fit efficiently.4 In a clinical study, 100% of patients fitted with clariti® 1 day multifocal 3 Add were successfully fitted with two pairs of lenses or less.4

“For ECPs, the combination of a simplified fitting process and strong fit success data makes a real difference in practice,” said Chithra Dhanabalan, Professional Affairs Manager, UK & Ireland, at CooperVision. “Presbyopic patients often present with complex visual needs, and the new clariti® 1 day multifocal 3 Add gives practitioners confidence that they can deliver optimised vision1 and comfort2,3 with an easy fitting experience.4 That means more time building patient relationships, and better outcomes for wearers who rely on their lenses every day.”

The Complete clariti® 1 day Portfolio

The full family of clariti® 1 day lenses – sphere, toric, and multifocal – offers high levels of comfort6 and features easy handling9 and high oxygen transmissibility (up to 2x the Dk/t of some hydrogel one day toric lenses), 10-12 which allows for 100 per cent corneal oxygen consumption to help maintain ocular health during daily wear.

For more information on this innovation and the wider CooperVision portfolio, visit: coopervision.co.uk

# # #

About CooperVision 

CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of one-day, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges, such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas, and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, California, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding a product launch and features and technologies that may impact demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies’ Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company’s analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

Media Contact
Naomi Snuggs

Just Communications

naomi@justcommunications.co.uk 
07733 233647

 

Footnotes

*Distance logMAR VA -0.05 vs -0.02 (p < 0.01), near VA 0.06 vs 0.11 (p = 0.02) for BPS vs 2 Add respectively.

† Warning: UV-absorbing contact lenses are not substitutes for protective UV-absorbing eyewear, such as UV-absorbing goggles or sunglasses, because they do not completely cover the eye and surrounding area. Patients should continue to use UV-absorbing eyewear as directed.

‡ With higher oxygen delivery than hydrogel materials, SiH contact lenses minimise or eliminate hypoxia-related complications during daily lens wear.

§ clariti® 1 day orders includes products sold and distributed by CooperVision in participating countries.

à Net plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram of plastic that may reach or be destined for waterways. CooperVision purchases credits equal to the weight of plastic in clariti® 1 day in a specified time period. clariti® 1 day plastic is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink).

¶ Based on manufacturers published data (up to 3X sphere and multifocal and up to 2X toric).

References

  1. CVI data on file, 2026.

  2. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add with a rating of 88 out of 100; n=90 habitual MFCL wearers.

  3. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with a rating of 93 out of 100; n=90 habitual MFCL wearers.

  4. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; n=90 habitual MFCL wearers.

  5. CVI data on file, 2019. Prospective, bilaterial, subject-masked dispensing study with clariti® 1 day multifocal. N=48 habitual soft MFCL wearers at 2 sites in North America, at baseline.

  6. CVI data on file, 2024.

  7. CVI data on file, 2022. Prospective, crossover, bilateral, subject masked, daily wear, dispensing study (4 clinical sites in U.S.) (n=58 habitual soft MFCL wearers).

  8. CVI data on file, 2022

  9. CVI data on file 2022. Verve Online Brand Survey with ECPs who recommend somofilcon A for new wearers in US, Spain, Italy, UK and Korea. n=249 (89% strongly agree/agree).
  10. Brennan NA. Beyond Flux: Total Corneal Oxygen Consumption as an Index of Corneal Oxygenation During Contact Lens Wear. Optom Vis Sci. 2005;82(6):467-472.
  11. Sulley A., Dumbleton K. Silicone hydrogel daily disposable benefits: The evidence. CLAE. 2020 Jun;43(3):298-307.

  12. Lumb E. & Symons A. Comparison of Dk/t values of daily disposable soft toric contact lenses using high resolution thickness profiling. BCLA Poster presentation at NCC 2016.

    CVC06261874-1

More News Articles